GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.

Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...

The initial three diamond drill holes at the El Perdido porphyry copper-gold-molybdenum prospect had target depths of 500 ...

Today, the Michigan Department of Health and Human Services (MDHHS) announced the launch of phase 2 enhancements to its statewide Bed Management Tool, according to a press release on Monday. The press ...

Figure 1 - Longitudinal view of the Phase 2 extension drilling program at Berrigan Mine: 3D longitudinal section showing ...

BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision ...

Missile detection satellite designed by BAE Systems passes early review Missile-tracking satellite designed by BAE Systems passes early review ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ...

The Delphi initiative—tied to the Greek oracle’s maxim “know thyself”—aims to support modular, chip-like sensors that could work in a variety of devices.

VDyne Inc. (“VDyne”), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of ...

Contract includes the potential for an additional $30 million in follow-on phases over the coming years, representing up to $60 million program value4M Defense will utilize its advanced autonomous rob ...